Two fast-growing epilepsy drugs and medicines advancing in its pipeline targeting impulse aggression and ADHD could make today’s drop worth buying.
Two fast-growing epilepsy drugs and medicines advancing in its pipeline targeting impulse aggression and ADHD could make today’s drop worth buying.